Skip to content

Pulse Biosciences, Inc. PLSE Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

PVL
Palvella TherapeuticsPVLA
$38.5K

Other financials

Income statement

See full
Revenue$401.0K
Gross profit$31.0K
Operating income-$19.2M-6.1%
Net income-$18.6M-10.6%
EPS (diluted)-$0.49-2.1%

Balance sheet

See full
Cash & equivalents$68.3M-42.7%
Total debt$7.2M-16.6%
Total equity$66.3M-44.0%
Total assets$81.6M-38.8%

Cash flow

See full
Operating cash flow-$14.6M-7.9%
CapEx$33.0K-26.7%
Free cash flow-$14.6M-7.8%

Valuation

See full
Market cap$1.77B+38.4%

Profitability

See full
Gross margin-4,067.5%
Operating margin-10,392.1%
Net margin-9,929%
FCF margin-7,390%

Returns & leverage

See full
Return on equity-80.7%+3.1pp
Debt / equity0.1×0.0×
Current ratio7.3×-8.3×

Where this comes from

Reported directly by Pulse Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulse Biosciences, Inc.'s payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulse Biosciences, Inc.'s payments of stock issuance costs?
Pulse Biosciences, Inc. (PLSE) reported payments of stock issuance costs of $57K in Q1 2026.
What does payments of stock issuance costs mean?
This metric represents the direct costs incurred in connection with the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. Monitoring these costs is essential for understanding the efficiency of the company's capital-raising activities and the net impact on cash reserves.